News
WINT
4.940
+14.09%
0.610
Weekly Report: what happened at WINT last week (0422-0426)?
Weekly Report · 6d ago
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.08% to 1644.11. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 04/24 14:00
(WINT) - Analyzing Windtree Therapeutics's Short Interest
Windtree Therapeutics's short percent of float has risen 30.3% since its last report. The company has 39 thousand shares sold short, which is 0.43% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/23 15:00
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Healthcare On the Move: Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers. S&P 500 Health Care Sector +0.08% to 1620.1. Moolec Science SA, NKGen Biotech, ProKidney among top gainers.
Seeking Alpha · 04/22 14:01
Weekly Report: what happened at WINT last week (0415-0419)?
Weekly Report · 04/22 11:37
Why Windtree Therapeutics (WINT) Stock Is Getting Hammered
Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading lower by 20% to $0.32. The company announced it approved a 1-for-18 reverse stock split of its common stock. The stock split will be effective April 19, 2024.
Benzinga · 04/18 17:27
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Las Vegas Sands Corp. Shares dipped 6.8% to $46.81 on Thursday. The company reported better-than-expected first-quarter results. AGBA Group Holding Limited shares jumped 148% after the company announced a merger agreement with Triller. Other stocks moving in the mid-day session included 23andMe Holding Co. And Vertex Pharmaceuticals.
Benzinga · 04/18 15:32
Windtree Therapeutics approves reverse stock split
Seeking Alpha · 04/18 12:04
*Windtree Therapeutics: Split Will Increase Market Price Per Shr of Company's Common Stk, Bringing Co Into Compliance With Listing Requirements of $1 Minimum Bid Price Requirement by Nasdaq Cap Market >WINT
Dow Jones · 04/18 12:02
*Windtree Therapeutics Announces 1-For-18 Reverse Stk Split >WINT
Dow Jones · 04/18 12:01
WINDTREE THERAPEUTICS ANNOUNCES REVERSE STOCK SPLIT
Reuters · 04/18 12:00
WINDTREE THERAPEUTICS INC: APPROVED A 1-FOR-18 REVERSE STOCK SPLIT OF ITS ISSUED AND OUTSTANDING COMMON STOCK, PAR VALUE OF $0.001 PER SHARE
Reuters · 04/18 12:00
Windtree Therapeutics GAAP EPS of -$0.95
Seeking Alpha · 04/17 17:55
Windtree Therapeutics GAAP EPS of $1.04, revenue of $58.72M
Seeking Alpha · 04/17 17:32
Windtree Therapeutics Q4 2023 GAAP EPS $(0.95) Misses $(0.94) Estimate
Benzinga · 04/17 12:19
*Windtree Therapeutics: Cash and Cash Equivalents $4.3M as at Dec. 31 >WINT
Dow Jones · 04/17 12:02
WINDTREE THERAPEUTICS INC - QTRLY NET LOSS OF $5.2 MLN ($0.95 PER BASIC SHARE)
Reuters · 04/17 12:00
WINDTREE THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS AND PROVIDES KEY BUSINESS UPDATES
Reuters · 04/17 12:00
Press Release: Windtree Therapeutics Reports -2-
Research and development expenses were $8.3 million for the year ended December 31, 2023. The Company reported an operating loss of $20.6 million. Windtree Therapeutics is a biotechnology company focused on advancing innovative therapies for critical conditions and diseases.
Dow Jones · 04/17 12:00
Press Release: Windtree Therapeutics Reports -3-
Liabilities The company has a total of 3,996 liabilities and assets. The company's liabilities include deferred tax liabilities and other liabilities. The Company's total liabilities are estimated to be more than $30 billion. The debt-to-equity ratio of the company's common stock is higher than the ratio of its common stock.
Dow Jones · 04/17 12:00
More
Webull provides a variety of real-time WINT stock news. You can receive the latest news about Windtree Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About WINT
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.